靶向人表皮生长因子受体3治疗非小细胞肺癌的研究进展  

Advances in HER3-Targeted Therapy for Nonsmall Cell Lung Cancer

作　　者：郑昌言 蒋家豪 宋戈 胡庆华[1] ZHENG Changyan;JIANG Jiahao;SONG Ge;HU Qinghua(School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Shanghai Henlius Biologics Co.Ltd.,Shanghai 201615,China)

机构地区：[1]中国药科大学药学院,江苏南京211198 [2]上海复宏汉霖生物医药有限公司,上海201615

出　　处：《药学进展》2023年第9期706-716,共11页Progress in Pharmaceutical Sciences

摘　　要：人表皮生长因子受体3(HER3/ERBB3)属于HER家族的成员,在多种癌症中广泛表达。在配体神经调节素激活下,HER3主要与表皮生长因子受体1(EGFR/ERBB1/HER1)和表皮生长因子受体2(HER2/ERBB2)形成异源二聚体,激活信号转导通路,促进肿瘤的发生和发展。研究表明,HER3不仅与非小细胞肺癌(NSCLC)的不良预后相关,且在患者耐药中起到重要作用,是NSCLC的潜在治疗靶点。目前,HER3靶向治疗药物尚未获得上市批准,但多个HER3靶向治疗药物已经进入临床试验阶段。通过对HER3与NSCLC的相关性以及目前正处于临床试验中的HER3靶向治疗NSCLC的药物进行介绍,为HER3靶向治疗药物的研发提供参考。Human epidermal growth factor receptor 3(HER3/ERBB3),a member of the HER family,is widely expressed in a variety of cancers.Activated by the ligand neuregulin,HER3 forms heterodimers mainly with EGFR(ERBB1/HER1)and HER2(ERBB2)to activate signal transduction pathways and promote tumorigenesis and progression.Studies have shown that HER3 is not only associated with poor prognosis in non-small cell lung cancer(NSCLC),but also plays an important role in drug resistance in patients,making it a potential therapeutic target for NSCLC.Although no HER3-targeted therapy has been approved,several have entered clinical trials.This article describes the relevance of HER3 to NSCLC and the HER3-targeted therapy for NSCLC currently in clinical trials to provide reference for the research and development of HER3-targeted drugs.

关 键 词：表皮生长因子受体3 非小细胞肺癌 靶向治疗 

分 类 号：R979.1[医药卫生—药品]